Cortexyme (CRTX) Cash Flow Statement

Click line-items for a historical chart and %

Net income	17.76M
Amortization and depreciation	13.42M
Provision for prompt payment discounts	3.78M
Recovery of inventory allowances	1.37M
Impairment of product rights
Stock-based compensation	2.01M
Benefit from (provision for) deferred income taxes	884K
Accounts receivable	-19.17M
Inventories	-4.55M
Prepaid expenses, long-term accounts receivable and other assets	-4.05M
Accounts payable
Accrued expenses and license agreement liability
Income taxes receivable
Deferred revenue	0
Net cash provided by operating activities	28.4M
Purchase of property and equipment	-844K
Net cash used in investing activities	-10.83M
Proceeds from exercise of common stock options and warrants	773K
Excess tax benefit from stock-based compensation	12K
Principal payments on capital lease obligation	-75K
Net cash provided by financing activities	-4.21M
Net increase in cash and cash equivalents	13.36M
Cash and cash equivalents as of beginning of period	56.25M
Cash and cash equivalents as of end of period	69.61M

Entities mentioned with CRTX

View All Entities